NHL26 | The Australasian Leukaemia and Lymphoma Group

DOI number	10.58109/0219-pb05
Publisher	Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)	Australasian Leukaemia and Lymphoma Group (ALLG) Judith Trotman (Concord Hospital)
Date Made Available	2023
Dataset	Individual participant data (IPD) in aggregate form
Description of Dataset	Dataset includes: Data for 37 patients with relapsed follicular lymphoma PET response of all 37 registered patients at screening, 6 months post study treatment, and at diesease progression QoL data for all patients up to 18 months of follow-up 2 years of Rituximab and Lenolidomide treatmant data Follow-up treatment data for all patients up to 18months Comparsion of treatment arm data for coversion of PET+ to PET Progression Free Survival and Overall survival data
Funding	Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)	Chemotherapy
ANZCTR Reference	ACTRN12613000106730
Publication(s)	Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study
Dataset Access	Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au